Neither is common with tirzepatide, but both require evaluation
The GLP-1 Agonist Boom in ME/CFS, FM and Long COVID: Insights, Using it, Trials Underway by Cort Johnson | Nov 3, 2025 | COVID-19, Dempsey, Epstein-Barr Virus, GLP-1, Gut, Homepage, Immune, Inflammation, Kaufman, Mast cell activation syndrome, Mast cell activation syndrome, Neuroinflammation, Pathogens, POTS, RECOVER Initiative, Severe ME/CFS, Treatment Complex, chronic illness experts discuss what GLP-1 agonists can and can't do in diseases like ME/CFS, long COVID, and POTS
Scott Wiener Legislator Yeah, why don't we, why don't we just do that briefly
Well, thats because your body removes excess vitamins to maintain the compounds concentration
The medication creates the window